Regulation of Phosphatase Homologue of Tensin Protein Expression by Bone Morphogenetic Proteins in Prostate Epithelial Cells by Travis Jerde et al.
 
 
REGULATION OF PHOSPHATASE HOMOLOGUE OF TENSIN PROTEIN 
EXPRESSION BY BONE MORPHOGENETIC PROTEINS IN PROSTATE EPITHELIAL 
CELLS 
 
 
 
 
Travis J. Jerde Ph.D.,1 Zhong Wu Ph.D.,2 Dan Theodorescu M.D., Ph.D.,2 and Wade Bushman 
M.D., Ph.D.1 
 
 
 
 
1Department of Urology-University of Wisconsin School of Medicine and Public Health-, 
Madison, WI 53792 
 
2 Paul Mellon Urological Cancer Institute-University of Virginia Medical School, Charlottesville, 
VA 22908 
 
 
 
 
Running Title:  BMP-mediated PTEN in prostate epithelial cells 
 
 
Funding: Department of Defense Prostate Cancer Program award W81XWH-07-1-0092. T.J.J. 
was also funded by the Department of Molecular and Environmental Toxicology through training 
grant from the National Institute of Environmental health Sciences (NIEHS), T32ES007015. 
 
 
Correspondence: 
 
Travis J. Jerde, Ph.D. 
K6-561 Clinical Sciences Center 
600 Highland Avenue 
Madison, WI   53792 
608-265-8706 
Fax: 608-265-8133 
jerde@urology.wisc.edu 
 
bushman@urology.wisc.edu 
ZW2N@hscmail.mcc.virginia.edu 
DT9D@hscmail.mcc.virginia.edu
ABSTRACT 
 
 
Phosphatase homologue of tensin (PTEN) is the key endogenous inhibitor of phosphoinositide 
signaling and is the most commonly mutated gene in human prostate cancer.  The bone 
morphogenetic proteins (BMPs) are secreted developmental signaling molecules known to 
promote differentiation in the prostate. BMP ligands have been shown to inhibit prostate cancer 
cell line proliferation and tumor growth and expression of BMPs, BMP ligands, receptors and 
signaling effectors are diminished in prostate cancer. A previous report in the colon led us to 
investigate the potential mechanistic relationship between PTEN and BMP signaling in prostate 
epithelial cells. We show here that BPM signaling positively regulates PTEN in normal and 
malignant prostate cells by increasing mRNA expression and stabilizing PTEN protein.  Further, 
we show that BMP attenuates prostate cell growth at least in part through its effects on PTEN.   
BMP treatment did not further inhibit the growth of conditional PTEN over-expressing cells, and 
stable shRNA-PTEN transfectants were refractory to BMP-mediated growth inhibition. Loss-of-
function of PTEN in prostate cancer cells may render them insensitive to the normal 
differentiating and growth-inhibitory effects of BMPs.  These data are the first to identify a 
mechanistic linkage between BMP signaling and PTEN in normal prostate epithelial cells and to 
suggest coordinate dysregulation in prostate cancer. 
 
Keywords:  Prostate, epithelium, bone-morphogenetic protein, phosphatase homologue of tensin 
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INTRODUCTION 
 
 Phosphatase homologue of tensin (PTEN) is one of the most commonly associated mutated 
genes in prostate cancer, and its mutation is tightly correlated to poor clinical prognosis (Sircar et 
al., 2009). This protein functions as an endogenous intracellular modulator of the 
phosphoinositide-3-kinase (PI3K)-Akt pathway and therefore plays a central role in regulating 
proliferation in many epithelial cells (Cantley and Neel, 1999).  A key regulatory step in this 
cascade is phosphorylation of phosphoinositide-bisphosphate (PIP2) to generate PIP3 by PI3K, 
resulting in activation of phosphoinositide-dependent kinases (PDK) and activation of Akt by 
phosphorylation (Cantley and Neel, 1999).  PTEN acts as a phosphoinositide phosphatase to 
reverse this reaction and inhibit PI3K-Akt signaling (Cantley and Neel, 1999).  Therefore reduced 
expression or function of PTEN in cancer permits unregulated Akt activation and increased tumor 
cell proliferation (Groszer et al., 2001; Halvorsen et al., 2003). Numerous mitogens and cytokines 
impinge upon this pathway by activating secondary adaptor molecules such as src, focal adhesion 
kinase (FAK), and insulin-like receptor substrate (IRS) that initiate the PI3K-Akt signaling cascade 
(Frost and Lang, 2007; Arcaro et al., 2007; Xia et al., 2004; Ozes et al., 2001).  
 
 Studies of growth regulatory pathways in the developing prostate have identified a number 
of important morphogens including fibroblast growth factors, hedgehog ligands, cytokines 
including interleukins and transforming growth factor beta, Notch, wnt/beta-catenin and the bone 
morphogenetic proteins (BMPs) (Prins and Putz, 2008).   The BMPs are members of the TGF-beta 
superfamily and over 20 BMP ligands have been identified (Gazzerro and Canalis, 2006). The 
BMPs act by binding heterodimers of BMPR type II and type I receptors activating  members of 
the SMAD family of signaling intermediates, most particularly  SMADs 1, 5, and 8 (Gazzerro and 
Canalis, 2006). The readout of BMP signaling is phosphorylation of SMADs and changes in 
transcription of specific target genes (Gazzerro and Canalis, 2006). Previous studies have shown 
that the ligands BMP-4 (and its homolog BMP-2) and BMP-7  are expressed in the developing 
prostate and exert important effects on prostate growth and proliferation (Lamm et al., 2001; 
Grishina et al., 2005).  Interestingly, expression of BMP-2, 4, and 7 ligands, BMP receptors and 
intracellular signaling components is diminished in prostate cancer as compared to normal tissue, 
and BMPs have been shown to inhibit prostate cancer cell line proliferation and tumor growth 
(Miyazaki et al., 2004; Brubaker et al., 2004; Kim et al., 2004).  
    
Although it is widely accepted that genetic mutation of PTEN can contribute to tumor 
tumorgenesis, recent studies suggest regulation of PTEN expression and activity may also 
contribute to tumor growth (Tamguney and Stokoe, 2007). For example, studies have shown that 
PTEN protein expression is reduced in a significant number of breast cancers (Engin et al., 2006). 
Although, the precise mechanism behind reduced PTEN protein levels in these cancers is poorly 
understood, repression of PTEN expression as well as changes in the activity and stability of 
PTEN protein have been proposed. Multiple signals could lead to positive or negative modulation 
of PTEN expression, including TGFβ signaling, UV radiation, and EGR-1 and PPAR signaling 
(Li and Sun, 1997; Stiles, 2009). Interestingly, BMP signaling has been demonstrated to sustain 
PTEN expression in the colon (Waite and Eng, 2003). Given the concurrent loss of expression of 
PTEN and BMP commonly observed in prostate cancer, we sought to investigate a possible 
mechanistic relationship between these pathways.   
 
RESULTS 
 
 We treated E6 and BPH-1 prostate epithelial cells with a concentration-response curve to 
BMP-4 and measured its effect on growth rate and PTEN protein expression. BMP-4 inhibited 
proliferation of E6 and BPH-1 cells in a concentration-dependent manner [Figure 1] and this 
inhibitory effect correlated with BMP-induced PTEN protein expression. Treatment with BMP-4 
significantly induced expression of PTEN protein in E6 (6-fold) and BPH-1 (2.5-fold). [Figure 2] 
This induction was concentration-dependent; the maximal effect in both cell lines was observed 
from treatment with 10 ng/ml BMP-4. Induction of canonical BMP signaling was confirmed by 
determination of activated (phosphorylated) SMAD (isoforms 1, 5, 8).  BMP-4 treatment and the 
associated induction of PTEN reduced PI3K-Akt signaling as evidenced by decreased 
phosphorylation of Akt (serine 473): BMP-4 reduced activated Akt by 39 (± 12) % in E6 cells, and 
by 33 (± 14) % in BPH-1 cells. [Figure 2].  Both the induction of PTEN and inhibition of 
proliferation by BMP-4 were completely blocked by the BMP antagonist NOGGIN.   
 
The LNCaP prostate cancer cell line is generally considered to be PTEN negative and no 
induction of PTEN expression or change in Akt activation was observed in LNCaP cells treated 
with BMP-4 (data not shown). Overexpression of PTEN in LNCaP-derived C4-2 cells consistently 
reduces proliferation, suggesting that PTEN activation is sufficient to inhibit growth (Wu et al., 
2007).  C4-2 cells engineered to express active PTEN from a doxacyclin-driven promoter exhibit a 
concentration-dependent inhibition of cell proliferation by doxacyclin (Wu et al., 2007). We 
treated these cells with increasing concentrations of doxacyclin in semi-log increments in the 
presence or absence of 10 ng/ml BMP-4 to examine the interaction of BPM-4 and PTEN [Figure 
3A].  BMP-4 did not inhibit proliferation of cells lacking significant promoter-driven PTEN 
expression (0 to 0.1 mg/ml doxacyclin). Intermediate concentrations of doxacyclin (0.3 μg/ml and 
1.0 μg/ml doxacyclin) produced partial growth inhibition that was significantly augmented by 
BMP treatment as evidenced by a log-fold leftward shift in the concentration-response curve. 
However, cells lacking significant promoter-driven PTEN expression (0 to 0.1 mg/ml doxacyclin) 
did not respond to BMP, and BMP failed to produce further growth inhibition in cells with full 
PTEN promoter-driven expression (3 mg/ml doxacyclin). The effect of BMP on growth inhibition 
was mirrored by PTEN protein induction. [Figure 3B] These data indicate that partial promoter-
driven PTEN expression is necessary for BMP-4 to significantly affect growth rate in C4-2 cells. 
  
We next sought to determine if the growth inhibitory effects of BMP-4 are dependent upon 
PTEN.  Transfection of E6, and BPH-1 cells with an siRNA construct, producing a minimum of 
70% expression knockdown, abrogated BMP-mediated growth inhibition [Figure 4].  BMP 
signaling was unaffected, as evidenced by SMAD 1, 5, 8 phosphorylation, but PI3K-Akt signaling 
activity was increased.  PTEN knockdown increased basal Akt phosphorylation and abrogated the 
decrease in Akt phosphorylation by BMP-4.  Non-silencing scrambled siRNA constructs had no 
effect on BMP-mediated growth inhibition. PTEN knockdown had an expected measurable 
inductive effect on PI3K-Akt signaling as measured by phosphorylated Akt. These data indicate 
that the growth-slowing effect of BMP-4 on prostate cell lines is at least in part due to its ability to 
induce PTEN expression. 
 
 We next sought to determine if the effect of BMP-4 on PTEN expression is transcriptional, 
post-transcriptional, or translational, or post-translation. E6 cells treated with BMP-4 exhibit time-
dependent induction of PTEN mRNA levels, with significant induction evident at 8 hours of 
treatment. [Figure 5A] This is not associated with an increase in mRNA stability for PTEN 
message, indicating that BMP-4 is likely inducing PTEN at the transcriptional level.  In addition, 
BMP-4 treatment is associated with a rapid decrease in phosphorylated PTEN protein levels 
(residues 380, 382, and 383), despite an evident increase in total PTEN levels. [Figure 5C]. To 
investigate the effect of BMP treatment on PTEN protein stability, we treated E6 cells pre-exposed 
to either BMP-4 or vehicle with cyclohexamide (5 μM) for 0, 0.5, 1, 1.5, 2, 3, 4, 8, or 24 hours and 
measured PTEN protein levels. We found that 24 hours of BMP pretreatment caused a doubling in 
PTEN half-life (15.1 hours to 28.4 hours, p=0.03, n=4). [Figure 5D] These data indicate that 
BMP-4 has a dual effect on PTEN expression that involves increased expression and enhanced 
protein stability.  
  
DISCUSSION 
 
 
 To our knowledge, this is the first paper to report on the mechanism by which bone 
morphogenetic proteins mediate prostate cell proliferation rates. The data indicate that treatment 
of prostate cell lines with BMP-4 results in increased cellular PTEN concentrations and a 
corresponding decrease in PI3K-Akt signaling. The data further show that PTEN increase is at 
least in part responsible for the decreased proliferation rate observed in prostate cell lines since 
siRNA knockdown of PTEN expression attenuates BMP-mediated decreases in cellular 
proliferation. PTEN increase involves both transcriptional and post-translational mechanisms, as a 
rapid increase in PTEN mRNA and an increase in PTEN protein stability were observed after 
BMP-4 treatment.  Experiments with conditional PTEN over-expressing cell lines further support 
a role for PTEN stability in cellular proliferation, as these cells required previous promoter-driven 
PTEN expression in order to respond to BMP-4 by PTEN expression increases and decreases in 
proliferation. Further, a decrease in phosphorylation of PTEN at residues 380, 382, and 383 are 
suggestive of enhanced PTEN activity, as these residues have been implicated in enzymatic 
activity in previous reports (Rahdar, et al., 2009). Future studies should be directed toward 
detailing the enzymatic effects of BMP signaling on PTEN function. 
 
 The BMP signaling pathway has critical roles in embryogenesis, organogenesis, cell 
growth, differentiation, cell migration and cell death (Miyazaki et al., 2003). Due to the diversity 
of these biological functions, it is not surprising that BMPs have been associated with control of 
proliferation and differentiation in normal and malignant prostate epithelial cells (Miyazaki et al., 
2004; Brubaker et al., 2004; Kim et al., 2004).  BMP-4 and BMP-7 are androgen-regulated genes 
that play critical roles in the proper regulation of prostate development by inhibiting epithelial 
proliferation, ductal budding and branching (Grishina et al., 2005). Specifically, BMP signaling is 
believed to promote differentiation of prostate epithelial cells, thereby repressing proliferative 
capacity (Grishina et al., 2005; Cook et al., 2007). In addition, the BMP antagonist Noggin is 
expressed in the developing mouse prostate and neutralizes inhibition of epithelial proliferation by 
BMP4 allowing ductal budding and regulation of bud outgrowth (Cook et al., 2007). Our data 
suggest that in depth study of a possible interplay of BMP and PTEN / PI3K-Akt signaling is 
warranted to further the mechanistic understanding of BMP signaling in prostate development. 
 
With regard to prostate cancer however, divergence in expression and function among the 
BMPs is evident in published reports and there are considerable inconsistencies in published 
results regarding the biological function of BMPs in prostate cancer cells. For example, BMP-6 
expression is upregulated in prostate cancers relative to noncancerous epithelium (Darby et al., 
2008), while BMP-2, BMP-4, and BMP-7 expression is decreased (Masuda et al., 2004). Yet, 
BMP-4, BMP-6 and BMP-7 have all been consistently detected in prostate cancer bone metastases 
and expression of proteins involved in the BMP signaling pathway are often observed in 
metastatic prostate cancer (Feeley et al., 2005). While several reports show a growth-reducing and 
differentiating effect of BMPs similar to what occurs in prostate development, other findings 
support a tumor-promoting role (Yang et al., 2005; Ye et al., 2007). These inconsistencies 
illustrate a pronounced uncertainty in this field, and the data presented in this manuscript may 
contribute to resolving some of these uncertainties. Specifically, the PTEN status of a particular 
tumor may be critical in determining how that tumor may respond to BMP expression: a PTEN-
positive cell may respond in growth inhibitory/pro-differentiation direction while a PTEN-
negative cell may respond in the opposite direction. 
 
Invasion and migration are processes of particular interest regarding BMP signaling in 
prostate cancer. Yang et al have reported that BMP-7 increased invasiveness and migration on PC-
3 cells, yet Feeley et al. reported no effects of BMP-7 on migration or invasion of these same cells 
(Feeley et al., 2006). Dai et al showed that BMP-7 (and BMP-2/4) did not alter invasion and 
migration of LuCaP and C4-2B cells (Dai et al., 2005). Yet, Ye et al have reported that inhibition 
of BMP-7 expression in PC-3 cells increases the invasive potential and migration of cells while 
reducing their proliferation (Ye et al., 2007). This process was dependent upon the loss of BMP 
signaling antagonists noggin and follistatin. It would be interesting to know how PTEN expression 
affects the results in this model, and future studies should be directed at determining if BMP-
mediated invasion and metastasis of high-grade prostate cancer cells is modulated by the PTEN-
Akt pathway.  
 
 While it is well-established that PTEN loss of function or suppression of expression is 
associated with prostate cancer growth and progression, recent papers have begun to define a role 
for PTEN in prostate cell migration and metastases (Wu et al., 2007). Cell migration in PTEN-
negative C4-2 cells is inhibited by ectopic PTEN expression and is dependent upon activity of the 
lipid phosphatase function of PTEN and corresponding decrease in PI3K-Akt signaling (Wu et al., 
2006).23  Similarly, PTEN-deficient cells exhibit increased cell motility, and PI3K-Akt signaling 
plays an important role in the regulation and directionality of cell migration (Shukla et al., 2007). 
In addition, bladder cancer cells exhibit PI3K-Akt-dependent epidermal growth factor-mediated 
chemotaxis (Gu et al., 1999; Theodorescu et al, 1998). Our data demonstrate that BMP signaling, 
known to play a critical role in cell migration and metastases, regulates PTEN expression. This 
further implicates PTEN expression status of the tumor as a possible intermediary factor in how a 
tumor responds to BMP, and may explain inconsistencies in the literature involving prostate 
cancer responses to BMP signaling.     
 
Our work shows that a strong signaling interrelationship exists between two signaling 
molecules known to be lost or down-regulated during prostate cancer growth and progression: the 
BMP and PTEN pathways. BMP-4 causes the induction of PTEN expression in prostate epithelial 
cells and is involved in stabilizing PTEN protein, resulting in significantly increased PTEN 
protein levels and the slowing of cell proliferation. In addition, previously published reports have 
implicated BMP signaling and the PI3K/Akt pathway in cell migration and metastases of prostate 
tumors, therefore future studies regarding the effect of BMP mediated PTEN expression on these 
critical processes should yield interesting results. Further future studies modulating both the BMP 
and PTEN pathways may have clinical relevance in the understanding and treatment of prostate 
cancer. 
 
MATERIALS / SUBJECTS AND METHODS 
 
Cells and culturing conditions: E6 prostate epithelial cells were kind gifts from Dr. David 
Jarrard, Department of Urology, University of Wisconsin Madison, and were cultured in 
conditions as previously published (Schwarze et al., 2002).21  The immortalized cells were 
screened for HPV16 E6 protein expression by Western blot analysis and were cultured for over 
20 passages to confirm immortality. BPH-1 cells were kindly provided by Dr. Simon Hayward, 
Vanderbilt University, Nashville, TN and were grown and maintained in conditions previously 
published (Hayward et al., 1995). The doxycyclin (DOX)-inducible C4-2 primary cell line (C4-2 
pTetOn) cells were generated by Dr. Zhong Wu under the supervision of Dr. Dan Theodorescu 
and have been previously described (Wu et al., 2006). Cells were generated by transfection of 
pTRE2hyg PTEN-HA into C4-2 pTetOn cells; cells were maintained in 10% FBS/RPMI 1640 
medium.   
 
Growth rate determinations:  Equivalent passages within each prostate cell line were plated at 
5000 cells/well in 24-well plates.  After a 24 hour attachment period, cells were grown in their 
prescribed media with 0, 1, 10, or 100 ng/ml BMP-4 (R&D systems, Minneapolis, MN) in the 
presence or absence of 500 ng/ml noggin (BMP antagonist-BMP and noggin were co-incubated 1 
hour prior to addition to the cells to allow for binding). At time 0 and at 24 hour intervals, cell 
photos of each well were taken at consistent marked locations in quadruplicate. All cell growth 
experiments were performed 4 times (n=4) for each cell line. Cell numbers were determined for 
each treatment and are reported as number of cells per 20X field. Each point is the mean ± S.E.M. 
of the total cell counts.  
 
Protein extraction, SDS-PAGE, and immunoblotting:  Isolated prostate cells were 
homogenized in protease inhibitor-containing lysis buffer (150 mM NaCl, 10 mM Tris, 1 mM 
EDTA, 1 mM benzenesulfonyl fluoride, and 10 µg/ml each of aprotinin, bestatin, L-leucine, and 
pepstatin A).  Triton X-100 was added to a concentration of 1%, and the homogenate was 
incubated on ice for 60 minutes, followed by centrifugation for 20 min at 14,100xG at 4C.  The 
supernatant was collected and total protein concentration was determined by BCA assay (Pierce, 
Rockford, IL). Proteins (20 µg/well) were resolved by electrophoresis in 4-20% gradient SDS-
polyacrylamide electrophoresis gels.  Proteins were transferred to PVDF membranes, blocked 
overnight [10 g/L nonfat dry milk, 10 g/L bovine serum albumin, and 0.5 g/L NaN3 in 1x 
phosphate-buffered saline (PBS; 2.7 mM KCl, 1.5 mM KH2PO4, 136 mM NaCl, 8 mM Na2HPO4) 
+ 0.05% (v/v) Tween 20] and incubated for 16 hours with one of the following primary antibodies: 
rabbit anti-PTEN (1:1000; Cell Signaling Technologies, Danvers, MA), rabbit anti-PO4-
S380,T382, T383-PTEN (1:250; Cell Signaling), rabbit anti-PO4-T308/473-Akt (1:100, Cell 
Signaling), rabbit anti-PO4 SMAD 1 [S463/465], 5[S463/465], 8 [S426/428] (1:1000, Cell 
Signaling). After washing six times in PBS + 0.05% Tween 20, the blots were incubated with goat 
anti-rabbit IgGs conjugated to horseradish peroxidase for one hour (1:200,000 dilution, Pierce, 
Rockford, IL) in 2.5 g/L nonfat dry milk, PBS, and 0.05% Tween 20.  Peroxidase activity was 
detected via West Femto® chemiluminescence reagent as directed by the manufacturer (Pierce).  
Photo images were analyzed by densitometry and ratios of protein of interest to GAPDH were 
determined and compared between treatments. 
 
Doxacyclin-inducible PTEN expression:  pTetOn-PTEN or C4-2 control cells (described above) 
were plated at a density of 10,000 cells per well in 6 well plates (for protein expression analysis) 
or 5000 cells/well in 24-well plates (for growth analysis) and grown in 10% FBS/ RPMI 1640 
medium. Analysis of PTEN protein expression: after reaching 90% confluency, cells were treated 
with concentrations of doxacyclin (0.03-3.0 μM in semi-log increments) and either 10 ng/ml 
BMP-4 or vehicle (0.2% BSA in PBS) overnight (16 hours). Cells were collected and protein was 
extracted and analyzed as described previously.  Analysis of growth rate: 5000 cells were plated 
per well in 24-well plates and allowed to attach for 24 hours.  Cells were then treated with 
concentrations of doxacyclin (0.03-3.0 μM in semi-log increments) and either 10 ng/ml BMP-4 or 
vehicle (0.2% BSA in PBS) in 10% FBS/ RPMI 1640 medium. At time 0 and at 24 hour intervals, 
cell photos of each well were taken at consistent marked locations in quadruplicate. All cell 
growth experiments were performed 4 times (n=4) for each cell line. Cell numbers were 
determined for each treatment and are reported as number of cells per 20X field. Each point is the 
mean ± S.E.M. of the total cell counts. 
 
siRNA knockdown of PTEN expression:  Stable PTEN siRNA-expression clones of E6 and 
BPH-1 cell lines were generated using the Trans-LentiviralTM GIPZ packaging system and 
Expression ArrestTM shRNAmir lentiviral delivery method using conditions and methods 
instructed by the manufacturer (Open Biosystems, Huntsville, AL). PTEN siRNA gene constructs 
employed human PTEN sequence clone RHS4430-99328837. Briefly, shRNA coding constructs 
supplied by Open Biosystems were cloned into pGIPZ expression plasmids (expressing selection 
factors puromycin resistance and GFP expression) using the protocol supplied and transformed 
into TLA-HEK293T packaging cells to generate live Lentivirus. After ampicillin selection of 
expressing clones, Lentiviral-producing packaging cells were grown and the lysed product was 
collected and used to infect prostate epithelial cell lines plated to 50% confluency. After infection, 
epithelial cells were selected for expression by puromycin-resistance and sorted by flow cytometry 
for GFP expression to ensure gene transduction. Effective PTEN expression knockdown on the 
siRNA clones was confirmed by a minimum of 70% expression knockdown by immunoblotting. 
Growth rate and PTEN inducibility experiments were performed in these cells and those 
expressing a scrambled sequence siRNA previously shown not to effect gene expression by Open 
Biosystems.   
 
 
RT-PCR of mRNA levels: Prostate cell lines were grown to 90% confluency in 12 well plates 
using cell line-specific conditions as described above and treated with either 10 ng/ml BMP-4 or 
vehicle (0.02% BSA in PBS) for 2, 4, 8, or 24 hours. Cells were harvested in 350 μl Qiagen 
RNeasy RLT lysis buffer plus 2-mercaptoethanol, RNA was extracted using the RNeasy kit as 
directed by the manufacturer (Qiagen, Valencia, CA), and complementary DNA was made using 
reverse transcription as previously described (Jerde and Bushman, 2009). RT-PCR for PTEN 
expression was performed as published (Jerde and Bushman, 2009) using the following primers: 
S27 forward TCTTTAGCCATGCACAAACG; S27 reverse TTTCAGTGCTGCTTCCTCCT; 
PTEN forward GAAGACCATAACCCACCACA; PTEN reverse 
TACACCAGTCCGTCCCTTTC. Cycle to threshold was calculated as previously described, and 
expression of PTEN was calculated as a ratio to ribosomal S27 expression. Comparisons between 
groups were made with analysis of variance (ANOVA), with p<0.05 indicative of significant 
difference. 
 
PTEN mRNA decay assay: E6 prostate cell lines were grown to 80% confluency in 12 well 
plates using cell line-specific conditions as described above and treated with either 10 ng/ml 
BMP-4 or vehicle (0.02% BSA in PBS) for 16 hours. Cells were then treated with 5 μM 
actinomycin D, a transcriptional inhibitor. This concentration was shown to be optimal for 
inhibition of transcription in these cells in previous experiments. Separate wells of cells were 
harvested at time 0 and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 24 hours after addition of actinomycin in 
350 μl Qiagen RNeasy RLT lysis buffer plus 2-mercaptoethanol, RNA was extracted using the 
RNeasy kit as directed by the manufacturer (Qiagen, Valencia, CA), and complementary DNA 
was made using reverse transcription as previously described (Jerde and Bushman, 2009). RT-
PCR for PTEN expression was performed using the method and primers described above. Cycle to 
threshold was calculated, expression ratio of PTEN to ribosomal S27 expression was calculated 
for each sample. The amount of PTEN for each time point was calculated as a ratio to that at time 
0, and a degradation curve was made and linear regression analysis performed (excel) to determine 
the half-life of each mRNA. Comparisons between BMP and vehicle-treated cells were made with 
analysis of variance (ANOVA) with p<0.05 indicative of significant difference.  
 
PTEN protein stability assay: E6 prostate cell lines were grown to 80% confluency in 6 well 
plates using cell line-specific conditions as described above and treated with either 10 ng/ml 
BMP-4 or vehicle (0.02% BSA in PBS) for 16 hours. Cells were then treated with 1 μM 
cyclohexamide, a translational inhibitor. This concentration was shown to be optimal for 
inhibition of translation in these cells in preliminary experiments. Separate wells were harvested at 
time 0 and at 1, 2, 4, 8, 24, and 48 hours after addition of cyclohexamide in protease inhibitor-
containing lysis buffer. Protein was extracted and immunoblotting for PTEN and GAPDH was 
performed for each sample as described above. The protein expression ratio of PTEN to GAPDH 
was calculated for each sample. The amount of PTEN for each time point was calculated as a ratio 
to that at time 0, and a degradation curve was made and linear regression analysis performed 
(excel) to determine the half-life of PTEN protein. Comparisons between BMP and vehicle-treated 
cells were made with analysis of variance (ANOVA) with p<0.05 indicative of significant 
difference. 
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FIGURE LEGENDS 
 
Figure 1. BMP-4 slows the growth of prostate cell lines. Growth curves of E6 (A.) and BPH-1 
(B.) treated with vehicle (0.1% BSA), 1 ng/ml BMP-4, 10 ng/ml BMP-4, and 100 ng/ml BMP-4. 
Quantification reflects the number of cells per 20x field; data reflect the mean of 4 experiments 
with 4 determinations averaged in each experiment. Statistical considerations: * p<0.05 BMP-4 
versus vehicle, ANOVA. 
 
Figure 2. BMP treatment of prostate epithelial cell lines increases PTEN protein expression. A. 
Quantified data from immunoblots from 4 experiments: 10 ng/ml BMP-4 induced PTEN 
expression in E6 and BPH-1 cells, resulting in suppressed PI3K-Akt signaling, as measured by 
phosphorylated T308/S472 Akt. Data presented are mean +/- sem. Statistical considerations: * 
p<0.05 BMP-4 versus vehicle. B. Quantified data from immunoblots from 4 experiments; data 
presented are mean +/- sem. Statistical considerations: * p<0.05 BMP-4 versus vehicle; ** p<0.05 
BMP-4+Noggin versus BMP alone, analysis of variance (ANOVA). C. Immunoblots of prostate 
cells (1-4, E6; 5-8, BPH-1) treated with either vehicle (0.1% BSA, lanes 1, 5, 9), 10 ng/ml BMP-4 
(lanes 2, 6, 10), 100 ng/ml Noggin (lanes 3, 7, 11), and BMP-4 pre-incubated (30 minutes) with 
Noggin (lanes 4, 8, 12). 
 
Figure 3. BMP-4 exerts PTEN-dependent effects on C4-2 growth. PTEN negative C4-2 cells were 
engineered to express a doxacyclin (dox)-inducible PTEN gene in which PTEN expression is 
dose-dependently induced by dox. Cells with little or no PTEN induction by dox were unable to 
respond to BMP-4 by either cell growth inhibition [A] or PTEN protein expression. [B] However, 
upon moderate dox stimulation (0.1-1.0 μg/ml dox), BMP-4 repressed growth and enhanced 
PTEN expression.  
 
Figure 4. BMP-4 repressed cell growth in prostate epithelial cells is dependent on PTEN 
expression.  [A] BMP-4 was unable to fully repress growth of E6, and BPH-1 stably transfected 
with siRNA constructs against PTEN relative to cells transfected with a scrambled non-silencing 
siRNA. Expression of the siRNA construct itself caused a substantial induction in growth rate 
further demonstrating the importance of PTEN in controlling growth rate in prostate epithelial 
cells. Data presented reflect the number of cells per 20x field; data presented are the mean of 4 
experiments with 4 determinations averaged in each experiment. Statistical considerations: * 
p<0.05 BMP-4 versus vehicle, ANOVA. [B] siRNA knockdown of PTEN prevented BMP-
mediated induction of PTEN expression and inactivation of Akt signaling, as determined by 
immunoblotting. Activation of SMAD signaling is unaffected, demonstrating that the BMP 
signaling axis remains intact in PTEN siRNA-transfected cells. 
 
Figure 5. BMP-4 sustains PTEN protein expression in prostatic epithelial cells post-translationally 
by reducing PTEN protein degradation. [A] BMP-4 treatment of E6 cells induces PTEN mRNA 
expression gradually over 24 hours of treatment as determined by RT-PCR. BMP-4 treatment had 
no effect on PTEN mRNA stability, as determined by actinomycin D treatment [B]. However, 
BMP treatment of E6 cells causes a marked reduction in phosphorylated PTEN (P-S380, 
T382/383 PTEN) despite increasing amounts of total PTEN (t-PTEN) [C], suggesting that PTEN 
protein conformation and activity may be affected by BMP.  PTEN protein stability is 
significantly enhanced by BMP-4 treatment as determined by cyclohexamide treatment [D]. 
Inhibition of the 26S proteosome with 10 μM MG-132 results in similar protein stabilization 
effects on PTEN (not shown).  
 





